- Home
- MGF vs EDIT Comparison
MGF vs EDIT Comparison
Compare MGF & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGF
- EDIT
- Stock Information
- Founded
- MGF 1987
- EDIT 2013
- Country
- MGF United States
- EDIT United States
- Employees
- MGF N/A
- EDIT N/A
- Industry
- MGF Trusts Except Educational Religious and Charitable
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGF Finance
- EDIT Health Care
- Exchange
- MGF Nasdaq
- EDIT Nasdaq
- Market Cap
- MGF 99.7M
- EDIT 99.9M
- IPO Year
- MGF N/A
- EDIT 2016
- Fundamental
- Price
- MGF $3.06
- EDIT $1.21
- Analyst Decision
- MGF
- EDIT Buy
- Analyst Count
- MGF 0
- EDIT 14
- Target Price
- MGF N/A
- EDIT $8.08
- AVG Volume (30 Days)
- MGF 104.4K
- EDIT 2.7M
- Earning Date
- MGF 01-01-0001
- EDIT 02-26-2025
- Dividend Yield
- MGF 7.64%
- EDIT N/A
- EPS Growth
- MGF N/A
- EDIT N/A
- EPS
- MGF N/A
- EDIT N/A
- Revenue
- MGF N/A
- EDIT $61,759,000.00
- Revenue This Year
- MGF N/A
- EDIT N/A
- Revenue Next Year
- MGF N/A
- EDIT N/A
- P/E Ratio
- MGF N/A
- EDIT N/A
- Revenue Growth
- MGF N/A
- EDIT 150.95
- 52 Week Low
- MGF $2.91
- EDIT $1.12
- 52 Week High
- MGF $3.46
- EDIT $11.58
- Technical
- Relative Strength Index (RSI)
- MGF 43.74
- EDIT 34.45
- Support Level
- MGF $2.95
- EDIT $1.17
- Resistance Level
- MGF $3.09
- EDIT $1.27
- Average True Range (ATR)
- MGF 0.04
- EDIT 0.11
- MACD
- MGF -0.00
- EDIT 0.04
- Stochastic Oscillator
- MGF 61.11
- EDIT 20.00
About MGF MFS Government Markets Income Trust
MFS Government Markets Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income. The fund invests a majority of the net assets, including borrowings for investment purposes, in U.S. and foreign government securities.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.